

BioPlex™ 2200 HSV-1 & HSV-2 IgG

Generating type specific results through advanced multiplex technology

Herpes Simplex Virus is prevalent worldwide. HSV-1 subtype is most commonly associated with oral lesions and HSV-2 subtype with genital lesions. To diagnostically differentiate HSV-1 from HSV-2, type-specific glycoproteins can be targeted. The BioPlex™ 2200 HSV-1 & HSV-2 IgG kit simultaneously detects and differentiates the two most clinically relevant IgG antibodies (in human serum or plasma) on a fully-automated, random access platform.

BioPlex™ 2200 type-specific beads for HSV:

- HSV-1 IgG
- HSV-2 IgG


BioPlex™2200 HSV-1 & HSV-2 IgG

Herpes Simplex Pathobiology

Glycoproteins that exhibit strong immunological responses in patients with herpes infection are targets for diagnostic as well as therapeutic utility. The Herpes Simplex Envelope contains at least 11 glycoproteins that exhibit significant protein and DNA (50%) homology between the two herpes immunological variants, type 1 (HSV-1) and type 2 (HSV-2).

Bio-Rad has taken advantage of some minor antigenic variation in glycoprotein G (also referred as gG) between the two subtypes in order to develop type-specific polypeptide probes for detecting IgG antibodies to HSV-1 and HSV-2. This was achieved by constructing the HSV-1 specific recombinant antigen and HSV-2* specific synthetic peptide conjugated to BSA.

* Bio-Rad BioPlex HSV-2 is a patented technology



Benefits of Multiplex HSV-1 & HSV-2 IgG Testing

- Fully-automated, random access multiplex assay procedure for HSV-1 & HSV-2 IgG testing from primary tube to final result
- Takes one patient sample and consolidates 2 traditional single-analyte tests into 1 kit for type-specific results
- Time to first result in approximately 45 minutes, 200 results per hour thereafter
- Ready-to-use multiplexed calibrators and controls, with curve stability up to 30 days

Quality and Performance

- Excellent HSV-1 and HSV-2 negative agreement with an FDA cleared Western Blot method: Sexually Active Individuals 90.1% and 98.2% respectively; Expectant Mothers 99% and 100% respectively; Low-prevalence population 97.9% and 97.8% respectively^a
- Excellent HSV-1 and HSV-2 positive agreement with an FDA cleared Western Blot method: Sexually Active Individuals 97.6% and 90.6% respectively; Expectant Mothers 96.3% and 96.9% respectively; Low-prevalence population 93.3% for HSV-1^a
- Excellent precision and reproducibility with between-run and within-run CVs under 7%
- For every sample processed, three internal quality controls are also processed, improving confidence in results

^a Please refer to Instructions for Use (IFU)

Ordering Information

Catalog No.	Description	
665-3350	BioPlex™2200 HSV-1 & HSV-2 IgG Reagent Pack.....	1 pack
663-3300	BioPlex™2200 HSV-1 & HSV-2 IgG Calibrator Set.....	1 set
663-3330	BioPlex™2200 HSV-1 & HSV-2 IgG Control Set.....	1 set



**Bio-Rad
Laboratories**

For further information, please contact the Bio-Rad office nearest you or visit our website at www.bio-rad.com/diagnostics

Clinical Diagnostics Group

Website www.bio-rad.com/diagnostics U.S. 1-800-2BIO-RAD Australia 61-2-9914-2800 Austria 43-1-877-8901 Belgium 32-9-385-5511 Brazil 5521-3237-9400
 Canada 1-514-334-4372 China 86-21-64260808 Czech Republic 420-241-430-532 Denmark +45-4452-1000 Finland 358-9-804-22-00 France 33-1-47-95-60-00
 Germany +49-(0)89-318-840 Greece 30-210-7774396 Hong Kong 852-2789-3300 Hungary +36-1-459-6100 India 91-124-4029300 Israel 972-3-9636050 Italy +39-02-216091
 Japan 81-3-6361-7070 Korea 82-2-3473-4460 Mexico 52(55)5200-0520 The Netherlands +31-318-540666 New Zealand 64-9-415-2280 Norway 47-23-38-41-30
 Poland 48-22-3319999 Portugal 351-21-472-7700 Russia 7-495-721-14-04 Singapore 65-6415-3188 South Africa 27-11-442-85-08 Spain 34-91-590-5200
 Sweden 46-8-555-127-00 Switzerland 41-61-717-95-55 Thailand 662-651-8311 United Kingdom +44-(0)20-8328-2000